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Many chemicals shown to be teratogenic in laboratory animals are not known to be teratogenic in
humans. However, it remains to be determined if the unresponsiveness of humans is due to lessened
sensitivity, togenerally subteratogenic exposure levels, ortothe lackofanappropriate meansofidentifying
human teratogens. On the other hand, with the exception of the coumarin anticoagulant drugs, those
agents well accepted as human teratogens have been shown to be teratogenic in one or more laboratory
species. Yet, no single species has clearly distinguished itselfas being more advantageous in the detection
of human teratogens over any other. Among the species used for testing, the rat and mouse most suc-
cessfully model the human reaction, but the rabbit is less likely than other species to give a false positive
finding. Among species less commonly used for testing, primates offered a higher level of predicability
than others. Regarding concordance of target malformations, the mouse and rat produced the greatest
number of concordant defects, but they also were responsible for the most noncorcordant responses as
well. Since no other species is clearly more predictive of the human response, it is concluded that safety
decisions should be based on all reproductive and developmental toxicity data in light ofthe agent's known
pharmacokinetic, metabolic and toxicologic parameters.
Introduction
The extrapolation ofanimal data to the human is the
foundation of safety evaluation of chemicals and drugs
prior to human exposure. As will be shown, there is at
present no perfectly suitable animal model from which
to make these extrapolations in most cases, nor is it
abundantly clear just what endpoints residing in the
animal database are most important in this determi-
nation. In short, it is conceded that the predictive value
of animal teratogenicity tests in extrapolating results
into terms of human safety is imperfect. Consider the
fact that of over 2800 chemicals now reported to have
been assayed in animals for teratogenic potential, only
about 14 chemicals or groups of chemicals have been
shown to have this propensity in humans (1). Put an-
other way, there are about 1000 or so chemicals that
demonstrate some measure ofteratogenicity in animals
but for which we have no evidence at all that they share
this property in humans. However, this discrepancy
may only reflect that we cannot clearly recognize ter-
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atogenicity in humans. It should be realized from the
onset that testing strategies of drugs for teratogenic
potential on the one hand need to be clearly distin-
guished from testing of industrial or environmental
chemicals on the other. Conditions of exposure, num-
bers of potential victims of exposure, benefit consid-
erations, economics and other factors are radically
different in the two cases and affect both the philosophy
of testing and the acceptable risk (2).
Fortunate as we are that newly identifiable human
teratogens have not wreaked havoc in the same manner
as in the 10,000 thalidomide victims in 1961 to 1962, or
in the 20,000 rubella-infected children in 1964, corre-
lations of animal and human responses may not be pro-
viding us with the necessary answers to avoid potentially
similar situations in the future. It is the apparent lack
ofassociation that precludes accurate prediction ofter-
atogenic potential in extrapolating from animals to hu-
mans. We are really left at present with the dilemma
of not being capable of selecting which animal species
are the most predictive of the likely human response.
Two decades ago, with the thalidomide catastrophe,
the rabbitemerged asthe sensitive species with respect
to this teratogen, highlighted in part because of the
negative and/or inconclusive results produced in a large
number of other laboratory species tested at the time.SCHARDEIN ET AL.
Enthusiasm for wider use of primates ensued soon
thereafter, chiefly on taxonomic grounds, but also due
to confirmatory results produced with thalidomide and
our inexperience in what to look for in an animal model
to predict teratogenicity. With the subsequent dem-
onstration that even subhuman primates did not re-
spond positively to several other suspected human
teratogens, the fact remains that the human female is
the only truly reliable model. However, a number of
reasons obviate against direct testing. Since the mid
and late 1960s, then, virtually every species maintained
in the laboratory (and some that were normally not!)
has been touted as a potential teratogenic model.
A number offactors relate to the inability to predict
accurately and the impreciseness in extrapolating from
one species to another, and include genetic heteroge-
neity (affecting absorption, metabolism and excretion
of a given chemical), and variability in diet, size, de-
velopmental patterns, intercurrent disease processes,
placental transfer, etc. It seems likely that variations
in metabolic pathways are a major cause ofspecies dif-
ferences (3).
The traditional endpoint in assessing teratogenic po-
tential is outright structural malformation. A given
chemical may, however, kill fetuses rather than mal-
form them at a given dose in one species, whereas it
may result in deformation among survivors at the same
dosage in another species. Further, the use of other
endpoints representing developmental toxicity, e.g.,
mortality or effects on growth or function, may be just
asappropriate asinducingteratain severalregards (see
below). Perhaps better correlation between laboratory
and the human species might be attained through col-
lectionandanalysisofallfeasibledevelopmentaltoxicity
endpoints. The purpose of this presentation therefore,
is to re-evaluate the species selection process in light
ofthe plethora ofinformation gathered on the potential
developmental toxicity and sensitivities of species to
therapeutic agents and environmental chemicals.
Historical Perspective
A laboratory animal to be used in evaluating human
teratogenic risk ideally would be chosen because it me-
tabolizes and distributes agiven chemical and transfers
it across the placenta in similar ways to man (4). Un-
fortunately, response toagivenchemicalbyaparticular
species ofanimal is almost as variable as the number of
chemicals tested.
Despite a wide range of species having been used in
teratology studies (2,5-8), no one species has been clearly
demonstrated to everyone's satisfaction to be the one
of choice to the exclusion of all others. This is particu-
larly true with regard to the few proven human tera-
togens, as will be amply demonstrated below. It need
only be recalled that the marked teratogenicity oftha-
lidomide in man has been observed in relatively few
species. Although some nine subhuman primate species
have demonstrated the characteristic limb defects ob-
served in humans when administered that drug, only 8
of 15 other putative human teratogens have been ter-
atogenic in one or more of the various primate species
(8).
Rodents are frequently used in teratogenicity stud-
ies. While the laboratory rat has been the most fre-
quently used rodent species, the susceptibility of this
species to putative teratogens has been variable, and
certain teratogens such as cortisone (4,9), thalidomide
(5,6), trimethadione (10), and lithium carbonate (11) have
elicited apoorteratogenicresponse. Micehavealsobeen
used frequently in teratology studies despite the marked
variability ofresponses observed with different strains
(12-14). Differences in intraspecies sensitivity has also
been reported for phenytoin (15) and ethanol (16,17).
Furthermore, stress-induced enhancement of already
comparatively high plasma corticosterone levels is be-
lieved to be the underlying mechanism facilitating stress-
related teratogenicity observed in the mouse (18,19).
Therefore, the mouse would seem unsuitable for the
testing of such agents as sedatives, tranquilizers, hyp-
notics or agents requiring unusual, manipulative pro-
cedures. The rat and rabbit are less prone to stress-
inducedteratogenicity (20,21). Alackofsteroid-induced
cleft palates in man led Tuchmann-Duplessis (6) to con-
clude that the unique susceptibilities encountered with
various mouse strains may lead to many false positives.
However, it can be said that inbred mouse strains are
probably more valid indicators than outbred strains in
assessing teratogenic potential (13).
Recently it has been suggested that hamsters may
serve as an appropriate rodent species for teratogen-
icity testing (22). A lack of data on spontaneous mal-
formations and intraspecies differences (23), while
offering no distinct advantage over more commonly used
rodent species (6), would tend to limit the usefulness of
this species. To date, only Canada includes hamsters as
a preferred animal of choice in teratogenicity testing
for regulatory decisions.
The guinea pig has also been suggested as an appro-
priate rodent species (24,25). Described as having a re-
productive endocrinology more closely related to man
than other rodents, limitations of a 68-day gestation
period, dependence upon an everted yolksac, and lack
of data concerning intraspecies differences may pre-
clude the common use ofthis species for teratogenicity
testing.
Rabbits have been used routinely as the nonrodent
species required by most regulatory agencies. As in the
case with rats and mice, the selection ofthis species has
been based largely on availability, economy, and long
history as a laboratory animal. While the rabbit's re-
sponsiveness to thalidomide has supported its appro-
priateness as a test species (26), it has not been
responsive to suchputativehumanteratogens asalcohol
(27) and lithium carbonate (11). In addition, this species
has limited use in the testing of antibiotics as induced
imbalances in the digestive microflora has led to ma-
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ternalmalnutrition, increased embryolethality and fetal
hypoplastic skeletal development (28).
It has been suggested that the ferret may serve as
an alternative to rabbits as the nonrodent species of
choice (29-32). Special problems ofdiet, seasonal breed-
ing, length of gestation (42 days), and insufficient his-
torical data may preclude the widespread use of this
species. However, unlike rodents and rabbits, but sim-
ilar to man, the ferret embryo is not maintained by an
everted yolksac placenta. Therefore, this species may
have merit in the teratogenic screening of compounds
whose mechanism of action involves the placenta (29).
The species has also been singled out as especially val-
uable in assessing behavior in the context ofreproduc-
tive toxicology (33).
Swine (34,35), dogs (34,36,37) and cats (5,38) have
been suggested as possible nonrodent species ofchoice.
All three species have been only variably responsive to
the teratogenicity of thalidomide. Further, limitations
of space, seasonal estrus, prolonged gestation, differ-
ences in xenobiotic metabolism, susceptibility to un-
derlying disease, and inadequate control data have
reserved the choice ofthese species for those occasions
when more conventional laboratory animals leave un-
answered questions.
Various species of primates have been suggested as
animals of possible selection for teratogenicity testing
(4,39-44). It must be emphasized that the close parallel
between man and monkey with regard to the terato-
genicityofthalidomide, norethindrone, testosterone, di-
ethylstilbestrol, and methylmercury (44) has not been
demonstrated forother chemicals which are teratogenic
in humans. In particular, methotrexate has been shown
to be teratogenic in man and rat, but macaque and rhe-
sus monkeys were refractory at doses equivalent to or
considerably higher than those above the usual human
dose (46). Similarly, attempts to duplicate in monkeys
the aminopterin teratogenicity observed in man showed
monkeys more susceptible to embryolethality than mal-
formation (47). On this basis, as well as the limitations
due to scarcity of these animals, it has been suggested
they not be used for widespread teratogenicity screen-
ing, butratherreservedfor casesofquestionableresults
from more commonly used laboratory animals orin tox-
icological evaluation of a very few selected agents
(6,47,48).
Despite a lack of agreement as to the most appro-
priate animal model, a general consensus exists as to
the necessary criteria for the selection ofsuch a model.
It is generally accepted by scientists and officials re-
sponsible forsafetyevaluation that, forrealistictesting,
thematernal-placental-embryonic relationship as char-
acterizedinmammalsisessential. Inaddition, metabolic
rates as well as the pathways ofxenobiotic metabolism
should be comparable to those of man. Parent com-
pounds and their respective intermediates should
undergo distribution, including transplacental crossing,
in a manner similar to that in human beings. Also, the
patterns ofembryonic andfetalstructuralandmetabolic
development should parallel those in man. Finally, the
idealanimalmodelshould be abletobe easilybred, have
a short gestation, produce large litters, and be econom-
ically housed and easily handled.
While it would be accepted at face value by all that
extrapolation to humans should be made from the most
sensitive animal species tested, the confidence in such
an extrapolation is increased as the number of species
tested increases, as will be discussed later. When dif-
ferent results are obtained from different species, it is
important to determine which of the test species more
closely resembles humans for the relevant underlying
mechanisms (49).
Since no single species thus far evaluated fulfills all
ofthe above criteria, thebestcompromisewould appear
tobethe selection oftwo ormore species. Thisapproach
hasbeenrecommended byothersrecently (50). As men-
tioned, past choicesbyscientists andregulatoryofficials
alike, have often been arbitrary, based solely on past
experiences and the availability of the test species.
Species Selection by Regulatory
Agencies
Without exception, principal regulatory agencies
throughout the world require the use of two species to
assess the teratogenic potential ofdrugs and chemicals
(Table 1). While tacit approval is given by several agen-
cies forthe use ofless common species, the requirement
in general mandates the use of one nonrodent and pre-
sumably, one rodent species. For all intents and pur-
poses, this is meant to imply the rat and rabbit. Although
the U.S. Food and Drug Administration (FDA) regu-
lations statethatthemouseandrabbithaveoccasionally
been preferable to the rat, rarely in practice has the
mouse substituted forthe rat. As with otherregulatory
agencies, the selection ofa species other than the mouse,
rat or rabbit has most often been reserved for those
casesofequivocalresultsfrommoreconventionallyused
species. The World Health Organization lists perhaps
thebroadestrange ofacceptable alternatives, including:
hamsters, guineapigs, ferrets, cats, pigs, dogs and non-
human primates, while the U.S. Environmental Pro-
tection Agency (EPA) allows for the selection of a
nonconventional laboratory species ifan appropriate ra-
tionale is given. Presumably such a rationale would be
based on similarities in xenobiotic metabolism, phar-
macokinetics, etc. However, inacknowledgingtheusual
lack ofsuch data, regulatory agencies often recommend
a species that is easy to use and characterized for its
response to known teratogens. The same stipulations
generally exist for other national regulatory agencies,
includingthose ofAustralia, West Germany, Spain, Ar-
gentina, Austria, Denmark, Finland, France, Ireland,
Italy, and Sweden. Paradoxically, one country, Nor-
way, requires the use ofone species in which the effect
ofthalidomidehasbeen documented (presumablyrabbit
or primate) in addition to either rat or mouse.
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Table 1. Species requirements according to selected governmental regulations guidelines.
Government Agency Species selection Comments Reference
U.S.A. FDA (drugs) At least two species. Most Although metabolism and trans- (51)
FDA (additives)
EPA (pesticides)
frequently used have been
the mouse, rat, and rabbit.
Mouse and rabbit have
occasionally been preferable to
the rat. Experience in monkeys
and other species limited, but
encouraged.
Species commonly used are the
rat, mouse, hamster, and rabbit.
Preference given to rat and
rabbit.
At least two mammalian species,
preferably rat and rabbit.
Allows for selection ofdifferent
species ifrationale appropriate.
placental passage mentioned
important for the selection of
an animal model for entire
reproduction studies, not
specifically mentioned as
essential to teratology
evaluation.
Common laboratory strains are to
be used. The strain should not
have low fecundity and should
be characterized for its response
to teratogens.
Commonly used strains should be
employed. Strain should not
have low fecundity and should
be characterized forits response
to teratogens.
(52)
(53)
Pesticides
Division of Agri-
culture Canada
Two species are to be chosen from
rat, mouse, hamster, and
rabbit
Bureau of Human
Prescription Drugs
Committee of Safety
of Medicines
(drugs)
Ministry of Health
and Welfare
(drugs)
Should be conducted on two
species. Frequently used have
been mouse, rat, and rabbit.
One should be a nonrodent
(rabbits are acceptable). With
uninterpretable results a third
species should be chosen.
In two animal species, one a non-
rodent. Third species other
than rodent or lagormorph if
results uninterpretable.
At least one species of rodent,
such as rats or mice, and one of
nonrodent, such as rabbits,
should be used.
Sometimes it is useful to compare
the pharmacokinetics of a drug
in nonpregnant and pregnant
animals to determine materno-
fetal distribution of drugs.
Suggest tests to see if pharmco-
kinetics differ in pregnant and
nonpregnant animals.
Prefer mammals of similar
metabolism to man. However, if
unknown use a species and
strain easy to employ, charac-
terized for its response to tera-
togens, and having a low back-
ground of deformities.
Ministry of
Agriculture and
Forestry (pesti-
cides)
OECD
(chemicals)
WHO
(drugs)
Sufficient number of more than
one kind ofexperimental animal
such as mice and rats are to be
used.
Commonly used are the rat,
mouse, hamster, and rabbit.
Preferable are the rat and
rabbit.
No recommendation as to
acceptable species. However,
should use two species, one a
nonrodent, if possible.
Use a common strain not of low
fecundity and characterized for
its response to teratogens.
Frequently used are mouse, rat,
and rabbit. However, the use of
hamsters, guinea pigs, ferrets,
cats, pigs, dogs, and non-
human primates is encouraged.
The reason for the apparent restriction to rat and
rabbit is probably twofold. First, these species have the
greatest historical control database available. In this
light, Japanese requirements further suggest that the
species of choice should have a low background of de-
formities. It is well known that intraspecies differences
in background malformation rates are not only more
consistent but significantly less in rats and rabbits than
Canada (54)
United
Kingdom
Japan
(55)
(56)
(57)
Europe
(common
market)
Worldwide
(65)
(59)
(60)
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Table 2. Discovery and method of ascertainment of human teratogens.
Probable
Teratogenic: establishment as
Tbratogen initial discovery human teratogen Method of ascertainment as
(species) Year Reference teratogen
Alcohol Rat 1973 (61) Cluster of similar cases
confirmed by epidemiological
studies
Androgenic/progestogenic hormones
Anticancer antimetabolites
Aminopterin
Fluorouracil
Methotrexate
Cytarabine
Anticancer alkylating agents
Busulfan
Chlorambucil
Cyclophosphamide
Mechlorethamine
Anticonvulsants
Hydantoins
Diones
Valproate
Antithyroid agents
DES
Rat
Human
Mouse
Rat
Rat
Rat
Mouse
Rat
Rat
Mouse
Human
Rat
Human
Rat
1953
1956
1980
1968
1980
1960
1963
1964
1974
1975
1975
1982
(62)
(63)
(64)
(65)
(66)
(67)
(68)
(69)
(70)
(71)
(72)
(73)
1940s-50s (various)
1970 (74)
Case reports, aided by similar
findings in animals
Case reports
Case reports
Case reports
Case reports
Case reports
Case reports
Case reports
Case reports
Epidemiological studies
Cases noted as part of genetic
evaluation
Epidemiological study
Case reports, aided by similar
findings in animals
Cluster of similar cases, con-
firmed by case collection in
Registry
Methylmercury
Thalidomide
Human
Human
Lithium Mouse
D-Penicillamine Human
Streptormycin antibiotics Human
Coumarin anticoagulants
Vitamin A analogs
Human
Rat
1959 (75)
1961 (76, 77)
1973
1971
(78)
(79)
1960s (Various)
1968
1983
(80)
(81)
Epidemiological study
Cluster of similar cases
Collection of cases via Registry
Case reports
Case reports aided by similar
findings in animals
Case reports
Case reports
in mice. Second, the scientific consideration is that the
species utilized in the assessment ofteratogenicity should
be that species which most closely resembles the human
with respect to metabolism, pharmacokinetics, excre-
tion, etc., and the rat undoubtedly would most likely
be the species under study in this regard. Increasing
emphasis ontherole ofpharmacokinetics isperhapsbest
exemplified by the suggestion of United Kingdom and
Canadian regulatory agencies that it may be useful to
compare the pharmacokinetics ofa drugin nonpregnant
and pregnant animals to determine the maternal-fetal
distribution of the drug. A final consideration is that a
"sensitive" species be used. Regulatory agencies ofthe
U.S., Japan, and Europe have suggested that the spe-
cies and strain used should be "characterized for its
response to teratogens," and as we shall note later, rats
and rabbits are susceptible to most known teratogenic
insults.
Identification of Human Teratogens
Recognition or identification of teratogens in the hu-
man is extremely tenuous for several reasons: thera-
peutic dosages or exposure levels are generally several
orders of magnitude lower than doses purposefully given
to animals to elicit malformations; pregnant women are
(hopefully!) not usually given long courses ofdrug ther-
apy nor a large number of drugs in this age of thera-
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Table 3. Predictability of laboratory animal models for putative human teratogens.a
Teratogen/group Mouse Rat Rabbit Hamster Primate Dog Cat Pig Ferret Guinea pig
Alcohol + + - + + + +
Androgenic hormonesb + + + + + + + +
Anticancer antimetabolitesc + + + + +
Anticancer alkylating agentsd + + + + +
Anticonvulsantse + _ + - +
Coumarin anticoagulants
Antithyroid agentsb + + + +
Progestrogenic hormonesb + + + - + +
DESb + + _ + + +
Methylmercury + + - + - - +
Thalidomide _ _ + - + + + + +
Lithium +
D-Penicillamine + +
Streptomycin antibioticsb - +
Vitamin A analogs + + + + + + + +
aLegend: (+) teratogenic; (±) variably teratogenic; (-) not teratogenic.
bDefects related to functional activity
'Includes azauridine, aminopterin, fluorouracil, methotrexate and cytarabine.
dIncludes busulfan, chlorambucil, cyclophosphamide, and mechlorethamine.
'Includes hydantoin and dione groups, and valproate.
peutic nihilism; the means ofproving causation or even
association in humans requires extensive analysis and
a large number of controlled cases, etc. In addition,
many chemicals which have demonstrated teratogenic
properties in animals have nonormal means ofexposure
to the human populace, and the human response has
simply never been put to test.
While with one exception all putative teratogens in
the human have been teratogenic in one or more labo-
ratory animal species as well, unfortunately it has not
been the case that discovery ofteratogenic potential of
a given chemical was made in animals prior to humans
(Table 2). Ofthe 22 individual or groups ofhuman ter-
atogenic chemicals listed, eight were first identified as
teratogens in the human. Included in the group are of
course the notorious thalidomide, aminopterin, and
methylmercury, all well known teratogens, perhaps
publicized more widely because of their initial identifi-
cation in the human species.
The method of detection of teratogens in the human
remains primarily astute clinicians' reports ofindividual
cases or, with several classic teratogens, e.g., thalido-
mide anddiethylstilbestrol, throughalmostintuitive ob-
servation of clusters of similar cases. The detection of
the latter chemicals was aided by the fact that the ab-
normalities observed in both examples were of such
rarity as to direct attention towards their occurrence.
Prior to the establishment of thalidomide as a causal
agent, for instance, phocomelia or amelia, the defect it
induced, occurred only very rarely (82); likewise, va-
ginal neoplasms had only been recorded in a few in-
stances in the entire world medical literature prior to
the causal association with diethylstilbestrol (83). Even
so, sufficient numbers of cases are required to ensure
recognition; solitary case reports do not demonstrate
association, let alone establish causation. Detection of
some of the remainder ofhuman teratogens on the list
has been much less fortuitous. Consider for instance,
that 15 years elapsed between the first recorded asso-
ciation of alcohol consumption and teratogenesis and
acceptance in the scientific community that alcohol was
the causal agent of a specific syndrome. Contrast this
tothe suspicion made regardingthalidomide in 1961 and
its removal from the market almost worldwide within
the course of less than one year.
The reliability of a particular animal study to predict
the fate of a chemical when applied to humans is never
fully known until sufficient epidemiological studies have
shown how the human responds to the substance. Thus,
the best evidence of an adverse human health effect
may well be aproperly conducted epidemiological study
(84-87). However, this has not been the case: in only
three instances-methylmercury, valproic acid, and the
hydantoin anticonvulsants-have epidemiological stud-
ies as opposed to any other means ofidentification been
the primary determinant of teratogenic potential.
Methods used to identify teratogenic hazards in hu-
manpopulations must, ofcourse, depend ontheirability
to identify an exposed group and documentation of ex-
posure (88). This is generally easiest for drugs, whose
useisusuallyrecorded; itisrelativelyeasyforchemicals
used socially for which individuals determine their own
pattern of usage and document it fairly reliably; it is
fairly difficult for occupational exposures, for which ex-
posed individuals canusually be identified but forwhich
themagnitude ofexposureisusuallydifficulttoestimate
and exposure to single chemicals is uncommon, and is
very difficult for environmental chemicals, for which
both the distribution and magnitude of exposures are
difficult to document.
Let us examine the process by which animal models
can be used to aid in predicting the human response to
teratogens: how the model reacts to known human ter-
atogens and how it reacts or overreacts to agents not
considered teratogens. In the former case, are the tar-
get sites the same?
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Table 4. Predictability of animal models to concordant human malformations.
Teratogen Reference malformation Concordant Nonconcordant
Alcohol Craniofacial, limb, CV Mouse, dog Rat, guinea pig, pig
Androgenic/progestogenic hormones Pseudohermaphroditism (9) Mouse, rat, guinea pig, hamster,
rabbit, dog, pig, primate
Anticancer antimetabolites
Aminopterin Skeletal Rat Dog, pig
Fluorouracil Multiple visceral Mouse, rat, guinea pig Rabbit, primate
Methotrexate Skeletal Rabbit, cat Mouse, rat, primate
Cytarabine Limb, ear Rat Mouse
Anticancer alkylating agents
Busulfan Multiple visceral Mouse, rat
Chlorambucil Urogenital Mouse, rat
Cyclophosphamide Digits Mouse, rat Rabbit, primate
Mechlorethamine Renal, limb, ear Rat, rabbit, ferret Mouse
Anticonvulsants
Hydantoins Facial, mental Mouse Rat, rabbit, primate
Diones Facial, mental Mouse, primate
Valproate CNS Mouse, rat, rabbit
Antithyroid agents Hypothyroidism Mouse, rat, guinea pig, rabbit
DES Uterine lesions Mouse, rat, primate, ferret
Methylmercury Microcephaly, mental Mouse, rat, cat Hamster
Thalidomide Limb Rabbit, primate Mouse, rat, hamster, dog,
cat, pig, ferret
Lithium CV Mouse
i-Penicillamine Skin lesion Rat Hamster
Streptomycin antibiotics Inner ear Rat
Vitamin A analogs CV, ear, brain Rat, mouse, hamster, dog, Rabbit, guinea pig, pig
primate
Predictability of Animal Models to
Human Teratogens
Chemicals or groups ofchemicals that are universally
recognized asbeingteratogenic tohumansundercertain
conditions of exposure are tabulated in Table 3. The
responses of the teratogens elicited in multiple labo-
ratory species are alsoincluded: itis apparentthat, with
one exception (coumarin anticoagulants), every chemi-
cal orchemical group knowntobeteratogenic inhumans
is also teratogenic in one or more laboratory species.
Thus positive animal teratology studies are at least
suggestive of potential human response.
With respect to responses of individual species, it
appears fromthis limited listthat theferret, guineapig,
mouse, and rat (in descending order) were the most
predictive ofthe human response. However, in the first
two species listed (ferret, guinea pig), testing was lim-
ited and may not be representative should more puta-
tive human teratogens be put to test in those species.
That leaves the mouse and rat most predictive, suc-
cessfully modeling the human reaction about 70% ofthe
time. In this limited series, the rabbit, hamster, pri-
mate, canine, and swine allidentified equallywell(about
40-50% of the time) the human response. The cat was
unacceptable in this regard, only identifying a single
human teratogen of the four tested.
In the only other analysis ofthis type, the mouse was
identified as the species most likely to yield a positive
result among 38 chemicals from which there were re-
ports of associated birth defects in humans (2).
Predictability of Concordant
Malformations
It is considered by many that to be successful, animal
models should mimic in the laboratory a similar or pre-
cise response to that of the human. Put another way,
the limb malformations in humans induced by thalido-
mide were replicated in certain breeds of rabbits and
in all but one primate species tested; these species are
therefore considered better models than are those spe-
cies in which malformations were induced by the drug,
but which were not concordant, or the same type or
pattern of reference malformation.
Concordant malformations to those induced by pu-
tative teratogens have been produced by one or more
species of laboratory animals with but several excep-
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tions (Table 4). Only several specific anticancer alky-
lating agents, several anticonvulsants, and lithium did
not produce a similar pattern of defects in animals to
those in humans. These data add credibility to use of
animal models in teratology, since more than halfofthe
known human carcinogens that have been adequately
testedin animals produced tumors in one or more animal
species at organ sites different from those produced in
exposed humans (89).
Individual species responses, however, were less per-
fect, with no species having especially good predictive
ability in type of teratogenic response. The mouse and
ratproducedthe greatestnumberofconcordant defects,
but they also were responsible for the most nonconcor-
dant responses as well.
Chemicals Not Teratogenic in Humans
Multispecies comparisons of animals exposed to the
same chemical might be useful in assessing risk to hu-
mans, the rationale being that there might be clues to
interspecies variability and sensitivity differences upon
such comparison. Most comparisons that have been made
represent direct animal-to-human extrapolation; ani-
mal-to-animal comparisons have been neglected in this
respect. Many studies in the biological literature give
results of testing numerous species for teratogenic po-
tentialofagivencompound, thereforeanimal-to-animal
comparisons canbemade. One studythathasbeenmade
addressingthese relationships wasreported recently by
one of us (8).
A summary ofthe multispecies comparisons indicate
that rabbits and monkeys offer greater predictability of
possible human responses than do any ofthe other spe-
cies (Table 5). Both species were responsive to all chem-
icals cited in only one-quarter of the cases. However,
it should be stated that the primate in particular has
been used for many of the cases to confirm the terato-
genicityofchemicals, especiallythosealreadysuspected
ofbeing teratogenic. Other commonly used species, in-
cluding mouse and rat, reacted negatively about 50 to
60% ofthe time. Some other species, such as hamster,
reacted positively to almost two-thirds ofthe chemicals
examined, indicatinglittle similarity tohumansinactual
teratogenic response.
In contrast to these results, rat and hamster re-
sponses were closest to those of humans in the nonter-
atogenic situationswith respecttodose-response ("best
response"). Mouseandpigalsohadclose responses more
thanhalfthe time, while rabbit and primate, the species
most representative of the human response from the
perspective ofoverallreaction, gavebest responses only
about 50% of the time, as did guinea pig.
Sensitivity comparisons indicated that rabbits and
primates again were the most predictive in nonterato-
genic situations, but this is to be expected since these
species gave nonteratogenic responses more frequently
than did the others. Cats were exquisitely sensitive,
but the responses to the few chemicals studies may not
Table 5. Summary of species-to-species extrapolation.a
Best Sensitivity, %C
Species na NT/T, %aresponse, %b _ +
Rat 322 60 71 30 29
Mouse 289 53 59 37 33
Rabbit 270 74 50 50 40
Hamster 93 38 71 31 17
Primate 59 72 49 53 18
Dog 44 52 43 39 33
Guinea pig 24 48 50 33 23
Pig 21 62 62 0 0
Cat 8 25 0 100 83
Ferret 5 40 50 50 33
an = Number ofreports evaluated for particular species; NT/T
ratio of nonteratogenic reports of selected nonteratogenic agents in
humans.
bMost similar to humans in nonteratogenic response = highest
nonteratogenic dosage.
'Lowest nonteratogenic dosage (-), lowest teratogenic dosage (+).
be respresentative of their full repertoire. When tera-
togenic responses were subjected to comparison, rabbit
again was the leader, with mouse, rat, and dog not far
behind.
Overall, analysis of data from this sort of animal-to-
animal extrapolation, though admittedly crude, further
indicated the wide variability of animal species in re-
sponse to biological testing. The data do point out, in
particular, however, that the use of rabbits and pri-
mates provides the greatest validity currently for pre-
dicting potential human teratogenicity.
Another FDA study addressing concordance of ani-
mal and human teratogenicity data came to a similar
conclusion with respect to most predictive species (2).
In the compilation reported, the monkey and the rabbit
gave the best negative response with respect to human
nonteratogens, providing correct (nonpositive) re-
sponses 80% and 70% of the time, respectively among
some 165 chemicals studied. Concordance for the rat
(50%), mouse (35%), and hamster(35%) was notasgood.
There are a number of chemicals that are of impor-
tancebecause ofoccupational exposurewhich areknown
animal teratogens but are not known to be teratogenic
in humans (Table 6). These chemicals are teratogenic
in one or more species of laboratory animals; epidemi-
ologic data are insufficient to determine their potential
to adversely affect human development. Because of
widespread human exposure to these chemicals in the
absence of sufficient epidemiologic data coupled with
theirknownteratogenicityinanimals, exposuretothese
chemicals should be managed conservatively, and epi-
demiology studies should be considered a high priority.
Another group of chemicals (Table 7) of occupational
and environmental importance have anecdotal reports
in the literature of adverse reproductive or develop-
mental outcomes. None of these chemicals are known
to be teratogenic in humans. With but several excep-
tions, these chemicals are also nonteratogenic or only
equivocallyteratogenic in laboratory animals and would
not be suspected as human teratogens based on the
animal data.
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Table 6. Chemicals teratogenic in laboratory and domestic animals which are not known to be teratogenic in humans."b
Species
Agent Rat Mouse Rabbit Hamster Other
Acrylonitrile
Aminoacetonitrile
Benomyl
Bis-(2-ethylhexyl) phthalate
N-Butyl methacrylate
p-tert-Butyltoluene
Cadmium
Carbaryl
Chlorfenvinphos
Chloroform
Chromium trioxide
Di-n-butyl adipate
Di-n-butyl phthalate
Dichloroisobutylene
Dieldrin
Di-2-ethylene adipate
Di-2-ethylhexyl phthalate
Diisobutyl adipate
Dimethoate
Di-2-methoxyethyl phthalate
Dimethylacetamide
Dimethyl adipate
Dimethyl phthalate
Dimethyl sulfoxide
2,4-Dinitrophenol
Dipropyl adipate
Endrin
Ethyl acrylate
Ethyl adipate
Ethylene glycol monomethyl ether
Ethylene glycol monoethyl ether
Ethylene oxide
Ethylene thiourea
Ethyl methacrylate
Ethyl methane sulfonate
Ethylnitrosourea
Ethyl phthalate
Ferbam
Heptachlor
Hexachlorobutadiene
Isobutyl methacrylate
Isodecyl methacrylate
Isopropyl methane sulfonate
Linuron
Malathion
Methoxychlor
N-Methyl acetamide
Methyl chloride
N-Methylformamide
Methyl methanesulfonate
N-Methylpyrrolidone
Mono-2-ethylhexyl phthalate
Monomethylacetamide
Monomethylformamide
Nickel carbonyl
Nitrobenzene
Nitrofen
2-Nitropropane
Paraoxon
Pentachlorophenol
Photomirex
Piperonyl butoxide
Polybrominated biphenyls
Propachlor
Propham
Propineb
Propoxur
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+ +
+ +
+ Sheep; ± monkey
± Pig; + dog; + goat
+
+
+ + - Sheep; - dog
+
+ Cat
+
+
+
+
+
+
+
+
+
+
+ + + Pig
- Cow
+
+
+
+
+
+
+
+
+
+ +
- Cow
+
(continued)
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Table 6. Continued
Species
Agent Rat Mouse Rabbit Hamster Other
Pentachloronitrobenzene - +
Sodium arsenate + + +
Sodium arsenite + +
Sodium cyanide + + +
Sodium fluoride + + + Dog
Sodium trichloroacetate +
Strontium salts + +
Succinonitrile +
Tetrachloroacetone + +
2,3,7,8-Tetrachlorodibenzofuran +
Tetramethylurea + +
Thiuram - + _ +
o-Toluenediamine +
Trichlorfon + + + + Pig
Trichloropropionitrile +
Trichlorotoluene +
Trifluralin +
a + Confficting or equivocal reports.
bSee reviews by Schardein (1) and John et al. (90).
Table 7. Chemicals with anecdotal reports of human reproductive or developmental effects.a,b
Species
Agent Rat Mouse Rabbit Hamster Implicated human findings
Acetone Birth defects
Benzene - + - Birth defects, chromosome aberrations
Boric acid - - Birth defects, sperm abnormalities
Butiphos Birth defects, stillbirths
Carbon disulfide + + Decreased fertility, spontaneous abortions
Carbon monoxide + - - Stillbirth, birth defect
Chloroprene + + Miscarriages
Dibromochloropropane Infertility
Dimethylformamide + - + Miscarriages
Dinitrodipropyl sulfanilamide ± Miscarriages, birth defects
Disulfiram Birth defects
Ethylene dibromide - - Decreased fertility
Formaldehyde + + Spontaneous abortions
Hexachlorobenzene ± + - Stillbirths, neonatal mortality
Lead + + - + Infertility, spontaneous abortion, birth defects
Mercuric chloride + Spontaneous abortion
Methylene chloride - - Birth defects
Methyl ethyl ketone + Birth defects
Methyl parathion - + Birth defects
Polychlorinated biphenyls Birth defects
Sodium selenite - - - Spontaneous abortion, birth defect
Styrene ± ± - - Abortion
Toluene - + Birth defects
Trichloroethylene - - - Birth defects
Vinyl chloride - - - Chromosome abnormalities, miscarriage,
stillbirth, sperm abnormalities, birth defects
Xylene - _ Birth defects
a + Confficting or equivocal reports.
bSee reviews by Schardein (1) and John et al. (83).
Predictability Based on Use of
Nontraditional Endpoints
Itishighlylikelythatanalysis ofendpoints otherthan
structural malformation might prove to be valuable ad-
juncts for use in estimation ofrisk from animal models
tothe human. Otherdataemergingfromdevelopmental
toxicity assessment, such as mortality, growth retar-
dation, fertility rate, and/or functional impairment are
the mostprominentparameters in thisregard. Todate,
these have not been utilized to the fullest possible ex-
tent. Since obvious malformations are unreliable indi-
cators ofteratogenicactivityinisolatedinitialscreening
tests, other parameters could be evaluated that often
associate with teratogenicity, that occur more fre-
quently and consistently and consequently are more
readily analyzable (91). Palmer (92) pointed out some
time ago that the low pregnancy rate, reduced litter
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Table 8. Developmental toxicity endpoints.
Incidence rates, %
Endpoint Mouse Rat Rabbit Primate Humana
Fertility 90
Malformation 1-19 1-2 1-6 0.3-0.5 7
Abortion - - 1 8.7-14.4 10-30
Prenatal mortality 1-29 19 28 2.5-36.5c
Neonatal mortaligy 0.5 12.9
Growth retardation 5-15
aData largely from Sholtz (94).
bOf livebirths.
cFrom 20th week gestation on.
size, and poor viability observed in the early animal
tests with thalidomide in rodents should have attested
to the potential hazard of this chemical, even in the
absence ofteratogenicity. Combining several endpoints
into risk assessment schemes has been recommended
for other toxicities, especially mutagenesis (93). Back-
ground data for several ofthese endpoints are given in
Table 8.
Discussion and Conclusion
Recognized human teratogens, except for coumarins,
are also teratogenic in laboratory animals. However,
many chemicals are teratogenic in laboratory animals
that are not known to be teratogenic in humans. Whether
this reflects lack of sensitivity of humans or lack of ap-
propriate datain humans is unknown. Also, some chem-
icals might in fact be teratogenic in humans at some
level ofexposure but are managed such that there is no
exposure of people to toxic levels.
There are sufficient epidemiologic data for many drugs
to determine the human response and thus assess the
predictability of animal data for human sensitivity. In
contrast, there are generally insufficient epidemiologic
data on most environmental and occupational chemicals
tojudge the predictability ofanimal data. Since animal
data predict the effects of most chemicals where we
have adequate human data, it is prudent to assume that
animal data are also predictive of the human response
to chemicals for which we have inadequate human data.
Among the species used for teratologic testing, the
rat and mouse are the most successful in modeling the
human reaction, but the rabbit is less likely than other
species to give afalse positive finding. No single species
is clearly more predictive of the human response than
others. Also, the organ systems or tissues affected in
laboratory animals are not necessarily predictive ofthe
type ofresponse in humans. Lack of an effect in a par-
ticular organ in animals does not predict the absense of
an effect in that organ in humans.
Assessment ofthe safetyofdrugsand otherchemicals
regarding teratogenic potential must take into account
the following points. The greater the number ofspecies
with positive results, the greater the likelihood of an
adverse effect in humans. All reproductive and devel-
opmental data should be used to predict safety, notjust
data on malformations. A regulatory approach based on
a number of similar considerations has been suggested
for carcinogens (95) and seems equally applicable to de-
velopmental toxins. The relevancy of the route of ex-
posure and existence of a dose-response relationship
are important for all species. Data from any species
must be used in the context of the total data base for
the agent, including pharmacologic, disposition, and
toxicologic data.
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